[1]BRAY F，FERLAY J，SOERJOMATARAM I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68(6)：394-424.
[2]EBCTCG EBCT.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival：An overview of the randomised trials［J］.Lancet，2005，365(9472)：1687-1717.
[3]SZOSTAKOWSKA M，TREBINSKA-STRYJEWSKA A，GRZYBOWSKA EA，et al.Resistance to endocrine therapy in breast cancer：Molecular mechanisms and future goals［J］.Breast Cancer Research and Treatment，2019，173(3)：489-497.
[4]HAQUE MM，DESAI KV.Pathways to endocrine therapy resistance in breast cancer［J］.Frontiers in Endocrinology，2019，10(1)：573-580.
[5]LI W，O' SHAUGHNESSY J，HAYES D，et al.Biomarker associations with efficacy of abiraterone acetate and exemestane in postmenopausal patients with estrogen receptor-positive metastatic breast cancer［J］.Clinical Cancer Research，2016，22(24)：6002-6009.
[6]HICKEY TE，IRVINE CM，DVINGE H，et al.Expression of androgen receptor splice variants in clinical breast cancers［J］.Oncotarget，2015，6(42)：44728-44744.
[7]CIMINO-MATHEWS A，HICKS JL，ILLEI PB，et al.Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy［J］.Hum Pathol，2012，43(7)：1003-1011.
[8]PONNUSAMY S，ASEMOTA S，SCHWARTZBERG LS，et al.Androgen receptor is a non-canonical inhibitor of wild-type and mutant estrogen receptors in hormone receptor-positive breast cancers［J］.iScience，2019，21：341-358.
[9]HE L，DU Z，XIONG X，et al.Targeting androgen receptor in treating HER2 positive breast cancer［J］.Sci Rep，2017，7(1)：14584-14593.
[10]GUCALP A，TOLANEY S，ISAKOFF SJ，et al.Phase II trial of bicalutamide in patients with androgen receptor-positive，estrogen receptor-negative metastatic breast cancer［J］.Clin Cancer Res，2013，19(19)：5505-5512.
[11]MCNAMARA KM，MOORE NL，HICKEY TE，et al.Complexities of androgen receptor signalling in breast cancer［J］.Endocr Relat Cancer，2014，21(4)：161-181.
[12]SULTANA A，IDRESS R，NAQVI ZA，et al.Expression of the androgen receptor，pAkt，and pPTEN in breast cancer and their potential in prognostication［J］.Transl Oncol，2014，4(4)：355-362.
[13]DE AMICIS F，THIRUGNANSAMPANTHAN J，CUI Y，et al.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells［J］.Breast Cancer Research and Treatment，2010，121(1)：1-11.
[14]SALVI S，BONAFE M，BRAVACCINI S.Androgen receptor in breast cancer：A wolf in sheep's clothing? A lesson from prostate cancer［J］.Semin Cancer Biol，2020，60：132-137.
[15]CLAESSENS F，DENAYER S，VAN TILBORGH N，et al.Diverse roles of androgen receptor(AR) domains in AR-mediated signaling［J］.Nuclear Receptor Signaling，2018，6(1)：6008-6020.
[16]NARAYANAN R，DALTON JT.Androgen receptor：A complex therapeutic target for breast cancer［J］.Cancers(Basel)，2016，8(12)：108-124.
[17]TAN MH，LI J，XU HE，et al.Androgen receptor：Structure，role in prostate cancer and drug discovery［J］.Acta Pharmacol Sin，2015，36(1)：3-23.
[18]PIETRI E，CONTEDUCA V，ANDREIS D，et al.Androgen receptor signaling pathways as a target for breast cancer treatment［J］.Endocr Relat Cancer，2016，23(10)：485-498.
[19]ANESTIS A，ZOI I，PAPAVASSILIOU AG，et al.Androgen receptor in breast cancer-clinical and preclinical research insights［J］.Molecules，2020，25(2)：358-368.
[20]VASILIOU SK，DIAMANDIS EP.Androgen receptor：A promising therapeutic target in breast cancer［J］.Crit Rev Clin Lab Sci，2019，56(3)：200-223.
[21]CHOI JE，KANG SH，LEE SJ，et al.Androgen receptor expression predicts decreased survival in early stage triple-negative breast Cancer［J］.Annals of Surgical Oncology，2015，22(1)：82-89.
[22]LIM E，NI M，CAO S，et al.Importance of breast cancer subtype in the development of androgen receptor directed therapy［J］.Curr Breast Cancer Rep，2014，6(2)：71-78.
[23]CHIA K，O' BRIEN M，BROWN M，et al.Targeting the androgen receptor in breast cancer［J］.Curr Oncol Rep，2015，17(2)：4-16.
[24]BASILE D，CINAUSERO M，IACONO D，et al.Androgen receptor in estrogen receptor positive breast cancer：Beyond expression［J］.Cancer Treatment Reviews，2017，61：15-22.
[25]LANZINO M，DE AMICIS F，MCPHAUL MJ，et al.Endogenous coactivator ARA70 interacts with estrogen receptor alpha(ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells［J］.J Biol Chem，2005，280(21)：20421-20430.
[26]DE AMICIS F，THIRUGNANSAMPANTHAN J，CUI Y，et al.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells［J］.Breast Cancer Research and Treatment，2010，121(1)：1-11.
[27]CIUPEK A，RECHOUM Y，GU G，et al.Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer［J］.Breast Cancer Research and Treatment，2015，154(2)：225-237.
[28]COCHRANE DR，BERNALES S，JACOBSEN BM，et al.Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide［J］.Breast Cancer Research，2014，16(1)：7-25.
[29]CAO L，XIANG G，LIU F，et al.A high AR∶ERalpha or PDEF∶ERalpha ratio predicts a sub-optimal response to tamoxifen therapy in ERalpha-positive breast cancer［J］.Cancer Chemother Pharmacol，2019，84(3)：609-620.
[30]CREEVEY L，BLEACH R，MADDEN SF，et al.Altered steroid milieu in AI-resistant breast cancer facilitates AR mediated gene-expression associated with poor response to therapy［J］.Mol Cancer Ther，2019，18(10)：1731-1743.
[31]TAKAGI K，MIKI Y，NAGASAKI S，et al.Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment［J］.Endocrine-Related Cancer，2010，17(2)：415-430.
[32]HANAMURA T，NIWA T，NISHIKAWA S，et al.Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism［J］.Breast Cancer Research and Treatment，2013，139(3)：731-740.
[33]RECHOUM Y，ROVITO D，IACOPETTA D，et al.AR collaborates with ERα in aromatase inhibitor-resistant breast cancer［J］.Breast Cancer Research and Treatment，2014，147(3)：473-485.
[34]AMARAL C，AUGUSTO TV，ALMADA M，et al.The potential clinical benefit of targeting androgen receptor(AR) in estrogen-receptor positive breast cancer cells treated with exemestane［J］.Biochim Biophys Acta Mol Basis Dis，2020，1866(5)：165661-165673.
[35]I KROP VAMC.Results from a randomized placebo-controlled phase 2 trial evaluating exemestane±enzalutamide in patients with hormone receptor-positive breast cancer［J］.Cancer Research，2018，78(4)：4-7.
[36]ELEBRO K，BORGQUIST S，SIMONSSON M，et al.Combined androgen and estrogen receptor status in breast cancer：Treatment prediction and prognosis in a population-based prospective cohort［J］.Clinical Cancer Research，2015，21(16)：3640-3650.
[37]ALI A，CREEVEY L，HAO Y，et al.Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer［J］.Breast Cancer Research，2015，17(1)：123-141.
[38]KRABY MR，VALLA M，OPDAHL S，et al.The prognostic value of androgen receptors in breast cancer subtypes［J］.Breast Cancer Res Treat，2018，172(2)：283-296.
[39]VERA-BADILLO FE，TEMPLETON AJ，DE GOUVEIA P，et al.Androgen receptor expression and outcomes in early breast cancer：A systematic review and meta-analysis［J］.J Natl Cancer Inst，2014，106(1)：319-329.
[40]QU Q，MAO Y，FEI XC，et al.The impact of androgen receptor expression on breast cancer survival：A retrospective study and meta-analysis［J］.PLoS One，2013，8(12)：82650-82657.
[41]VENEMA CM，BENSE RD，STEENBRUGGEN TG，et al.Consideration of breast cancer subtype in targeting the androgen receptor［J］.Pharmacology & Therapeutics，2019，200：135-147.
[42]ELEBRO K，BORGQUIST S，SIMONSSON M，et al.Combined androgen and estrogen receptor status in breast cancer：Treatment prediction and prognosis in a population-based prospective cohort［J］.Clin Cancer Res，2015，21(16)：3640-3650.
[43]RANGEL N，RONDON-LAGOS M，ANNARATONE L，et al.The role of the AR/ER ratio in ER-positive breast cancer patients［J］.Endocr Relat Cancer，2018，25(3)：163-172.
[44]PARK S，PARK HS，KOO JS，et al.Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers［J］.Breast Cancer Research and Treatment，2012，133(1)：311-320.
[45]HIlBORN E，GACIC J，FORNANDER T，et al.Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer［J］.British Journal of Cancer，2016，114(3)：248-255.
[46]BRONTE G，ROCCA A，RAVAIOLI S，et al.Androgen receptor in advanced breast cancer：Is it useful to predict the efficacy of anti-estrogen therapy［J］.BMC Cancer，2018，18(1)：348-355.
[47]KENSLER KH，REGAN MM，HENG YJ，et al.Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer：Results from the Breast International Group Trial 1-98［J］.Breast Cancer Research，2019，21(1)：30-40.
[48]ACETO N，BARDIA A，WITTNER BS，et al.AR Expression in breast cancer CTCs associates with bone metastases［J］.Mol Cancer Res，2018，16(4)：720-727.
[49]DE LAERE B，VAN DAM PJ，WHITINGTON T，et al.Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns［J］.Eur Urol，2017，72(2)：192-200.